Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TARGET: Ex Vivo Evaluation of hAMSC Secretome in IBD
NCT07721207Not yet recruiting
- Sponsor
- Policlinico Gemelli
- Start
- Nov 2026
- Primary completion
- Nov 2027
01
Overview
Single-arm trial in inflammatory bowel disease (IBD), sponsored by Policlinico Gemelli. Primary endpoints: Ex vivo modulation of immune cell populations at 7 days, Ex vivo modulation of inflammatory cytokines at 7 days and 1 more. Planned start Nov 2026; status: not yet recruiting.
02
Conditions
inflammatory bowel disease (IBD)
Beyond the preview
Go deeper on NCT07721207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07721207.